Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Allergy Therapeutics PLC on Thursday said it expects to swing to a loss for the full-year as revenue plummets on production disruptions.
Shares in Allergy Therapeutics were down 10% at 2.51 pence each in London on Thursday morning.
The West Sussex, England-based commercial biotechnology company, focused on the treatment and diagnosis of allergic disorders, said its underlying operating loss is expected to be around £13.3 million from a profit of £3.4 million the year before.
This results from an expected revenue of £61.0 million, 16% lower from £72.8 million a year prior.
This is due to a short-term halt in production between October and November last year, Allergy Therapeutics said.
Looking ahead, Allergy Therapeutics expects sales for financial 2024 to be slightly lower than financial 2023, as it forecasts costs and overheads before research and development costs to be higher.
The company added it will require funding from October onwards for trading, working capital and continuing research and development programmes.
Copyright 2023 Alliance News Ltd. All Rights Reserved.